HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mangiferin, a novel nuclear factor kappa B-inducing kinase inhibitor, suppresses metastasis and tumor growth in a mouse metastatic melanoma model.

Abstract
Advanced metastatic melanoma, one of the most aggressive malignancies, is currently without reliable therapy. Therefore, new therapies are urgently needed. Mangiferin is a naturally occurring glucosylxanthone and exerts many beneficial biological activities. However, the effect of mangiferin on metastasis and tumor growth of metastatic melanoma remains unclear. In this study, we evaluated the effect of mangiferin on metastasis and tumor growth in a mouse metastatic melanoma model. We found that mangiferin inhibited spontaneous metastasis and tumor growth. Furthermore, mangiferin suppressed the nuclear translocation of nuclear factor kappa B (NF-κB) and expression of phosphorylated NF-κB-inducing kinase (NIK), inhibitor of kappa B kinase (IKK), and inhibitor of kappa B (IκB) and increases the expression of IκB protein in vivo. In addition, we found that mangiferin inhibited the expression of matrix metalloproteinases (MMPs) and very late antigens (VLAs) in vivo. Mangiferin treatment also increased the expression of cleaved caspase-3, cleaved Poly ADP ribose polymerase-1 (PARP-1), p53 upregulated modulator of apoptosis (PUMA), p53, and phosphorylated p53 proteins, and decreased the expression of Survivin and Bcl-associated X (Bcl-xL) proteins in vivo. These results indicate that mangiferin selectivity suppresses the NF-κB pathway via inhibition of NIK activation, thereby inhibiting metastasis and tumor growth. Importantly, the number of reported NIK selective inhibitors is limited. Taken together, our data suggest that mangiferin may be a potential therapeutic agent with a new mechanism of targeting NIK for the treatment of metastatic melanoma.
AuthorsTomoya Takeda, Masanobu Tsubaki, Kotaro Sakamoto, Eri Ichimura, Aya Enomoto, Yuri Suzuki, Tatsuki Itoh, Motohiro Imano, Genzoh Tanabe, Osamu Muraoka, Hideaki Matsuda, Takao Satou, Shozo Nishida
JournalToxicology and applied pharmacology (Toxicol Appl Pharmacol) Vol. 306 Pg. 105-12 (09 01 2016) ISSN: 1096-0333 [Electronic] United States
PMID27417526 (Publication Type: Journal Article)
CopyrightCopyright © 2016 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Apoptosis Regulatory Proteins
  • Integrins
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • Xanthones
  • mangiferin
  • Protein Serine-Threonine Kinases
  • Matrix Metalloproteinases
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Apoptosis Regulatory Proteins (metabolism)
  • Integrins (genetics)
  • Male
  • Matrix Metalloproteinases (genetics)
  • Melanoma, Experimental (drug therapy, metabolism, pathology)
  • Mice, Inbred C57BL
  • Protein Kinase Inhibitors (pharmacology, therapeutic use)
  • Protein Serine-Threonine Kinases (antagonists & inhibitors)
  • RNA, Messenger (metabolism)
  • Xanthones (pharmacology, therapeutic use)
  • NF-kappaB-Inducing Kinase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: